Adequate Blood Pressure Target with Treatment
For adults with confirmed hypertension, the blood pressure target is <130/80 mm Hg for all patients, with encouragement to achieve systolic BP <120 mm Hg when feasible, particularly in those at increased cardiovascular risk. 1, 2
Risk-Stratified Treatment Targets
High Cardiovascular Risk Patients (≥7.5% 10-year PREVENT risk)
- Systolic BP: Target at least <130 mm Hg, with encouragement to achieve <120 mm Hg (Class 1, Level A recommendation) 1
- Diastolic BP: Target <80 mm Hg (Class 1, Level B-R recommendation) 1
- This intensive approach reduces cardiovascular events and total mortality 1
Lower Cardiovascular Risk Patients (<7.5% 10-year PREVENT risk)
- Systolic BP: Target <130 mm Hg may be reasonable, with encouragement toward <120 mm Hg (Class 2b, Level B-NR recommendation) 1
- Diastolic BP: Target <80 mm Hg may be reasonable (Class 2b, Level B-NR recommendation) 1
- This prevents further BP elevation over time 1
Treatment Initiation Strategy
When to Start Medication
Immediate pharmacotherapy is indicated for:
- Average BP ≥140/90 mm Hg in all adults 2
- Average BP ≥130/80 mm Hg in patients with:
- Clinical cardiovascular disease
- Previous stroke
- Diabetes mellitus
- Chronic kidney disease
- 10-year PREVENT risk ≥7.5% 2
Delayed pharmacotherapy approach:
- For BP ≥130/80 mm Hg with PREVENT risk <7.5%: attempt 3-6 months of lifestyle modification first
- If BP remains ≥130/80 mm Hg after this trial, initiate medication 2
Initial Medication Regimen
For stage 2 hypertension (≥140/90 mm Hg):
- Start with 2 first-line agents of different classes in a single-pill, fixed-dose combination 2
- This approach improves adherence and reduces time to BP control compared to separate pills 2
First-line drug classes include:
- ACE inhibitors or ARBs (renin-angiotensin system inhibitors)
- Calcium channel blockers (dihydropyridine)
- Thiazide-type diuretics 1
Critical Implementation Points
Measurement Accuracy
The entire treatment paradigm depends on accurate, standardized BP measurement 3. Home BP monitoring combined with frequent multidisciplinary team interactions using standardized protocols is essential 2. Avoid reliance on cuffless devices (smartwatches) until they demonstrate greater precision 2.
Monitoring for Adverse Effects
While intensive BP lowering is generally safe, monitor for:
- Hypotension and syncope
- Injurious falls
- Electrolyte abnormalities
- Reduction in eGFR 1
These adverse events are infrequent and usually mild, but require individualization in the minority who have difficulty tolerating treatment 1.
Common Pitfalls to Avoid
Do not combine drugs with overlapping mechanisms:
Do not actively aim for:
- SBP <120 mm Hg in frail patients or those with limited life expectancy
- DBP <70 mm Hg (some European guidelines caution against this) 4
Evidence Strength and Divergence
The 2025 AHA/ACC guidelines 1, 2 represent the most aggressive BP targets among recent international guidelines. This differs from 2024 ESC and 2023 ESH guidelines, which use alternative terminology ("elevated BP" vs "hypertension") for BP 130-139/80-89 mm Hg and recommend pharmacotherapy only in high-risk groups at these levels 4. The European guidelines also recommend avoiding actively targeting SBP <120 mm Hg 4.
However, the evidence supporting intensive lowering has strengthened, with multiple trials demonstrating cardiovascular benefit, including in diabetes and older adults 5. The observational data show a log-linear relationship between BP and CVD risk from 100-180 mm Hg systolic 1, supporting the "lower is better" principle within tolerable limits.
The principal challenge is no longer identifying effective treatments but delivering accurate measurement, timely intensification, and sustained follow-up 5. Team-based care with multidisciplinary involvement (physicians, pharmacists, nurses, community health workers) is effective in addressing barriers to BP control 2.